Jiangsu Hengrui says NMPA approves two new Hetrombopag olamine indications
Jiangsu Hengrui Pharmaceuticals Co Ltd said China’s NMPA has approved two new indications for its Hetrombopag olamine tablets. The company is listed on the SSE under 600276.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.